Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 23;6(10):e2339116. doi: 10.1001/jamanetworkopen.2023.39116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2023 Baltussen JC et al. JAMA Network Open.

This is an open access article distributed under the terms of the CC-BY License.

PMC Copyright notice

Figure 1. — Frequencies of grades 3 to 5 toxic effects (P = .01), nonhematologic toxic effects (P = .03), dose reduction during treatment (P = .04), early treatment discontinuation (P = .009), and hospitalization (P = .003) were significantly different between patients with and without frailty, analyzed with a χ² test.

^aP < .05.

^bThe worst grade of toxic effects was documented (grade e3). Of the patients who developed grades 3 to 5 toxic effects, 91% developed their first toxic effects within the first 2 months after chemotherapy initiation, and 9% developed their first toxic effects after 2 months.

^cAmong patients with frailty, reasons for early treatment discontinuation were toxic effects (64%), tumor progression (29%), death to other cause (3%), clinical deterioration (3%), or other reasons (1%). Among patients without frailty, reasons for early treatment discontinuation were toxic effects (56%), tumor progression (28%), or clinical deterioration (16%).